The Quantellect read.As of Nov 19, 2026, 8 active firms cover Biohaven Ltd: 4 rate it Buy or better, 3 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. The target range is very wide, $10.00 to $30.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $16.88 sits 31% above the current $12.91. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.46 next quarter toward $-1.53 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Neutral
Strong Buy00%
Buy450%
Neutral338%
Sell113%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$16.88
+30.7% upside
Average target across 8 active firms as of Nov 19, 2026 vs $12.91 current
Highest Target$30.00
Average Target$16.88
Lowest Target$10.00
Detailed analyst forecasts for BHVN
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 4 of 8 active firms rate BHVN a Buy (3 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BHVN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.46
Range $-0.46 – $-0.46 · 1 analysts · -33% YoY
Next period, 1 analysts expect Biohaven Ltd. to earn $-0.46 a share (range $-0.46 – $-0.46), versus $-0.69 a year earlier. Full-year consensus is $-1.39, growing to $-1.53 the year after.
REVENUE · NEXT QUARTER
$60.0M
Range $0 – $350.0M · 1 analysts
Revenue is expected to reach $60.0M (range $0 – $350.0M). Full-year consensus is $143.3M, rising to $103.9M next year.
Top analysts covering Biohaven Ltd.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BHVN.
#1
Leonid Timashev
RBC Capital · Rank #27
Neutral
$22.00+70.4% to target
Overall win rate
52%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #160
Sell
$11.00-14.8% to target
Overall win rate
47%
+ Follow
#3
Terence Flynn
Morgan Stanley · Rank #222
Buy
$19.00+47.2% to target
Overall win rate
36%
+ Follow
#4
Marc Goodman
Leerink Partners · Rank #251
Buy
$15.00+16.2% to target
Overall win rate
46%
+ Follow
#5
Douglas Tsao
HC Wainwright & Co. · Rank #312
Neutral
$10.00-22.5% to target
Overall win rate
35%
+ Follow
BHVN stock forecast FAQ
What is BHVN's average 12-month price target?+
The 8 active firms with a live target average $16.88 for Biohaven Ltd. over the next 12 months, ranging from a $30.00 high to a $10.00 low, as of Nov 19, 2026.
Is BHVN stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 8 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 3 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BHVN?+
The Street-high target is $30.00 (TD Cowen), and the Street-low is $10.00 (HC Wainwright & Co.). The average of all 8 active-firm targets is $16.88.
How many active Wall Street firms cover BHVN?+
8 active firms have a recognized rating on Biohaven Ltd. as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BHVN?+
Among analysts who currently cover BHVN, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #27). Their current call is Neutral with a $22.00 target.
What is Biohaven Ltd.'s projected EPS for next quarter?+
The consensus estimate is $-0.46 per share (range $-0.46 – $-0.46) across 1 analysts. Full-year EPS is projected at $-1.39, rising to $-1.53 the following year.
How much revenue is Biohaven Ltd. expected to report next quarter?+
Consensus revenue is $60.0M (range $0 – $350.0M). Full-year revenue is projected at $143.3M, growing to $103.9M next year.
Have analysts been upgrading or downgrading BHVN lately?+
As of Nov 19, 2026, 4 of 8 active firms rate BHVN a Buy (3 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BHVN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.